14.60Open14.60Pre Close0 Volume6 Open Interest340.00Strike Price0.00Turnover58.81%IV-3.14%PremiumMay 16, 2025Expiry Date24.52Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7303Delta0.0096Gamma10.68Leverage Ratio-0.4262Theta-0.0776Rho-7.80Eff Leverage0.1956Vega
Madrigal Pharmaceuticals Stock Discussion
Can Madrigal's Rezdiffra Breakthrough in Cirrhosis Patients Transform Liver Disease Treatment?
📊⚡️📊
MDGL gained as much as 15.2% to a $294.44 intraday high after Wolfe lauded the company's breakthrough liver drug Rezdiffra, according to published reports.
The U.S. Food and Drug Administration approved Rezdiffra in March as the first treatment fornonalcoholic steatoh...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$